Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Heather L. Benjamin, MD, James M. Rossetti, DO, Aaron J. Lampkin, MSIV, Christie Hilton, DO, Entezam Sahovic, MD, Haifaa Abdulhaq, Richard K. Shadduck, MD, Namratha Vemulapalli, MD, Amanda Hercules, MD, John Lister, MD

Blood (2009) 114 (22): 4164.

https://doi.org/10.1182/blood.V114.22.4164.4164

Published: 2009

Journal Articles

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

Haifaa Abdulhaq, MD, Bushra Haq, MD, James M. Rossetti, DO, Richard K. Shadduck, MD, Entezam Sahovic, MD, Dijana Christianson, DO, John Lister, MD

Blood (2008) 112 (11): 5072.

https://doi.org/10.1182/blood.V112.11.5072.5072

Published: 2008

Journal Articles

A Retrospective Analysis of Response to High Dose Rituximab Monotherapy in CLL/NHL Patients Who Received Prior Standard Dose Rituximab Therapy.

Casey A. Moffa, DO, Chandana Thatikonda, MBBS, Neeta Pathe, MD, James M. Rossetti, DO, Richard K. Shadduck, MD, John Lister, MD

Blood (2007) 110 (11): 4722.

https://doi.org/10.1182/blood.V110.11.4722.4722

Published: 2007

Journal Articles

Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation.

James M. Rossetti, DO, Richard K. Shadduck, MD, Chandana Thatikonda, MBBS, Entezam Sahovic, MD, John Lister, MD

Blood (2007) 110 (11): 5034.

https://doi.org/10.1182/blood.V110.11.5034.5034

Published: 2007

Journal Articles

Combination Methyltransferase and Histone Deacetylase Inhibition in Elderly Patients with Secondary Acute Myelogenous Leukemia.

Chandanda Thatikonda, MBBS, James M. Rossetti, DO, Richard K. Shadduck, MD, John Lister, MD

Blood (2007) 110 (11): 4387.

https://doi.org/10.1182/blood.V110.11.4387.4387

Published: 2007

Journal Articles

Reduced-Intensity Allogeneic Transplantation after Failure of Autologous Transplantation: A Prospective Multi-Center CALGB Study.

Asad Bashey, MD, PhD, Kouros Owzar, PhD, Jeffrey L. Johnson, Steven M. Devine, MD, Richard K. Shadduck, MD, Thomas C. Shea, MD, Charles Linker, MD

Blood (2006) 108 (11): 3122.

https://doi.org/10.1182/blood.V108.11.3122.3122

Published: 2006

Journal Articles

G-CSF Increases Hematological Response among Patients with Myelodysplasia Treated with Azacitidine.

James M. Rossetti, DO, Eric Falke, Richard K. Shadduck, MD, Joan M. Latsko, MSN, CRNP, AOCNP, Wendy Kramer, John Lister, MD

Blood (2006) 108 (11): 4868.

https://doi.org/10.1182/blood.V108.11.4868.4868

Published: 2006

Journal Articles

Thalidomide for the Treatment of Chronic Bleeding Secondary to Hereditary Hemorrhagic Telangiectasia and Gastrointestinal Vascular Malformations.

Marion B. Raflores, MD, Richard K. Shadduck, MD

Blood (2006) 108 (11): 3927.

https://doi.org/10.1182/blood.V108.11.3927.3927

Published: 2006

Journal Articles

Effect of Chemotherapy Treatment on Fetal-Maternal Microchimerism in Parous Cancer Patients.

Gary L. Gilmore, PhD, Melissa M. Holm, Bsc, Yuliya Anikanova, Bsc, Bushra Haq, MD, Sri Lakshmi Jasthy, MD, John Lister, MD, James M. Rossetti, MD, Richard K. Shadduck, MD

Blood (2006) 108 (11): 5134.

https://doi.org/10.1182/blood.V108.11.5134.5134

Published: 2006

Journal Articles

Selection of CD34 + HSC from Pooled Cord Blood Samples Does Not Result in Co-Purification of Potential Alloreactive CD3 + T Cells.

Gary L. Gilmore, PhD, Darlene K. DePasquale, BSc, John Lister, MD, Richard K. Shadduck, MD

Blood (2005) 106 (11): 5263.

https://doi.org/10.1182/blood.V106.11.5263.5263

Published: 2005

Journal Articles

Fetal-Maternal Microchimerism: Basis for a Potential New Therapy for Malignancy?.

Gary L. Gilmore, PhD, Melissa M. Holm, John Lister, MD, Richard K. Shadduck, MD

Blood (2004) 104 (11): 4941.

https://doi.org/10.1182/blood.V104.11.4941.4941

Published: 2004

Journal Articles

AML Induction Therapy with Outpatient Azacitidine.

Richard K. Shadduck, MD, James M. Rossetti, MD, Yacoub Faroun, MD, Robert B. Kaplan, MD, John Lister, MD

Blood (2004) 104 (11): 1800.

https://doi.org/10.1182/blood.V104.11.1800.1800

Published: 2004

NARROW

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

A Retrospective Analysis of Response to High Dose Rituximab Monotherapy in CLL/NHL Patients Who Received Prior Standard Dose Rituximab Therapy.

Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation.

Combination Methyltransferase and Histone Deacetylase Inhibition in Elderly Patients with Secondary Acute Myelogenous Leukemia.

Reduced-Intensity Allogeneic Transplantation after Failure of Autologous Transplantation: A Prospective Multi-Center CALGB Study.

G-CSF Increases Hematological Response among Patients with Myelodysplasia Treated with Azacitidine.

Thalidomide for the Treatment of Chronic Bleeding Secondary to Hereditary Hemorrhagic Telangiectasia and Gastrointestinal Vascular Malformations.

Effect of Chemotherapy Treatment on Fetal-Maternal Microchimerism in Parous Cancer Patients.

Selection of CD34 + HSC from Pooled Cord Blood Samples Does Not Result in Co-Purification of Potential Alloreactive CD3 + T Cells.

Fetal-Maternal Microchimerism: Basis for a Potential New Therapy for Malignancy?.

AML Induction Therapy with Outpatient Azacitidine.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only